Evolus (NASDAQ:EOLS) Hits New 12-Month High at $13.78

Evolus, Inc. (NASDAQ:EOLSGet Free Report)’s share price reached a new 52-week high during mid-day trading on Friday . The company traded as high as $13.78 and last traded at $13.57, with a volume of 540957 shares trading hands. The stock had previously closed at $13.36.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $27.00 price target on shares of Evolus in a research note on Wednesday, January 17th. Barclays raised Evolus from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $10.00 to $16.00 in a research report on Monday, January 29th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 target price on shares of Evolus in a research report on Wednesday, December 20th.

Check Out Our Latest Stock Report on EOLS

Evolus Stock Up 2.5 %

The business has a 50-day moving average price of $11.02 and a two-hundred day moving average price of $9.74. The company has a market capitalization of $783.64 million, a price-to-earnings ratio of -12.34 and a beta of 1.50.

Insider Buying and Selling

In related news, insider David Moatazedi sold 31,300 shares of the company’s stock in a transaction on Friday, December 8th. The stock was sold at an average price of $9.73, for a total transaction of $304,549.00. Following the completion of the sale, the insider now owns 603,944 shares in the company, valued at $5,876,375.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, Director Karah Herdman Parschauer sold 11,931 shares of the company’s stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $13.14, for a total transaction of $156,773.34. Following the completion of the sale, the director now owns 31,243 shares in the company, valued at $410,533.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider David Moatazedi sold 31,300 shares of the company’s stock in a transaction on Friday, December 8th. The stock was sold at an average price of $9.73, for a total value of $304,549.00. Following the sale, the insider now owns 603,944 shares of the company’s stock, valued at approximately $5,876,375.12. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 94,579 shares of company stock worth $979,424. 5.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Stonepine Capital Management LLC grew its stake in Evolus by 14.9% in the 3rd quarter. Stonepine Capital Management LLC now owns 5,179,004 shares of the company’s stock valued at $47,336,000 after purchasing an additional 672,807 shares during the period. BlackRock Inc. grew its stake in Evolus by 22.7% in the 2nd quarter. BlackRock Inc. now owns 2,995,386 shares of the company’s stock valued at $21,776,000 after purchasing an additional 554,417 shares during the period. Vanguard Group Inc. grew its stake in Evolus by 37.9% in the 3rd quarter. Vanguard Group Inc. now owns 2,698,647 shares of the company’s stock valued at $24,666,000 after purchasing an additional 741,451 shares during the period. Great Point Partners LLC grew its stake in Evolus by 11.0% in the 2nd quarter. Great Point Partners LLC now owns 2,434,048 shares of the company’s stock valued at $17,696,000 after purchasing an additional 241,232 shares during the period. Finally, Schroder Investment Management Group grew its stake in Evolus by 7.1% in the 3rd quarter. Schroder Investment Management Group now owns 1,752,595 shares of the company’s stock valued at $16,019,000 after purchasing an additional 115,647 shares during the period. Institutional investors own 65.15% of the company’s stock.

Evolus Company Profile

(Get Free Report)

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

See Also

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.